Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaQualia PharmaTSE:4579 60 14-Day RSI is 52.04 as of Aug. 03, 2026. GuruFocus rates TSE:4579 with a GF Score™ of 60/100 and a GF Value™ of 円311.11 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,422 Biotechnology companies, RaQualia Pharma ranks worse than 79.4% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-03), RaQualia Pharma's 14-Day RSI is 52.04.
The industry rank for RaQualia Pharma's 14-Day RSI or its related term are showing as below:
TSE:4579's 14-Day RSI is ranked worse than 79.4% of 1422
companies
in the Biotechnology industry
Industry Median: 44.07
vs TSE:4579: 52.04
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
RaQualia Pharma 14-Day RSI Related Terms
TSE:4579 vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, RaQualia Pharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a 14-Day RSI of 52.04 as of Aug. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #1129 out of 1422 companies in the Biotechnology industry, placing it in the top 79.4%.
Is RaQualia Pharma's 14-Day RSI too high?
RaQualia Pharma's current 14-Day RSI is 52.04. The Biotechnology industry median 14-Day RSI is 44.07. RaQualia Pharma's value of 52.04 is 18.1% above this industry median. Based on the distribution chart, RaQualia Pharma ranks #1129 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RaQualia Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #1129 out of 1422 companies for 14-Day RSI. This places RaQualia Pharma in the lower half of its industry. The industry median 14-Day RSI is 44.07. RaQualia Pharma's value of 52.04 is 18.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 44.07, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current 14-Day RSI of 52.04 is 18.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median 14-Day RSI is 44.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current 14-Day RSI is 52.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円311.11, compared to a current price of 円482.00 — trading 54.9% above its estimated fair value. The current 14-Day RSI is 52.04 and 18.1% above the Biotechnology industry median of 44.07. RaQualia Pharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current 14-Day RSI is 52.04 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued.
The current stock price of 円482.00 is trading 54.9% above its estimated GF Value™ of 円311.11.
GuruFocus considers RaQualia Pharma to be Significantly Overvalued.
Key valuation signals for TSE:4579:
14-Day RSI: 52.04
GF Value™: 円311.11 vs. price of 円482.00 (54.9% above fair value)
Industry Position: 18.1% above the Biotechnology median (#1129 of 1422)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
60GF Score
Get the complete analysis for TSE:4579
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
